# US 2020/0392230 A1 · Bispecific anti-cd3 x cd20 antibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392230 A1
- Document ID: US20200392230A1
- Status: Published application
- Kind: A1
- Application number: 15/930,933
- Filed: 2020-05-13
- Published: 2020-12-17
- Earliest claimed: 2019-05-14
- Assignees: QLB Biotherapeutics
- Applicants: QLB Biotherapeutics
- Inventors: Chao TU; Rijian WANG
- Web page: https://patentgrep.com/patent/US20200392230A1

## CPC

- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- A61P 35/00: Antineoplastic agents
- C07K 16/2887: {against CD20}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/522: CH1 domain
- C07K 2317/55: Fab or Fab'
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/74: Inducing cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The disclosure relates to bispecific anti-CD3×CD20 antibodies comprising (i) a single-chain CD3 binding moiety, (ii) a single-chain CD20 binding moiety, and preferably (iii) an Fc region. Aspects of the disclosure further relate to compositions comprising these bispecific antibodies, vectors comprising one or more polynucleotides encoding these bispecific antibodies, as well as uses of these bispecific antibodies for treating a subject suffering from a B cell-related cancer, in particular, a subject who has developed resistance to anti-CD20, e.g., rituximab, therapy.

## Claims

### Claim 1

A bispecific antibody comprising:
(i) a single-chain CD3 binding moiety comprising a heavy chain variable domain (VH) operably linked to a light chain variable domain (VL) via a first peptide linker, wherein
the VH comprises a heavy chain CDR1 comprising SEQ ID NO: 1, a heavy chain CDR2 comprising SEQ ID NO: 2, and a heavy chain CDR3 comprising SEQ ID NO: 3; and
the VL comprises a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6, and
(ii) a single-chain CD20 binding moiety comprising a VH operably linked to a VL via a second peptide linker, wherein
the VH comprises a heavy chain CDR1 comprising SEQ ID NO: 7, a heavy chain CDR2 comprising SEQ ID NO: 8, and a heavy chain CDR3 comprising SEQ ID NO: 9; and
the VL comprises a light chain CDR1 comprising SEQ ID NO: 10, a light chain CDR2 comprising SEQ ID NO: 11, and a light chain CDR3 comprising SEQ ID NO: 12.

### Claim 2 (depends on 1)

The bispecific antibody of claim 1, wherein
the VH in the single-chain CD3 binding moiety comprises SEQ ID NO: 22, and the VL in the single-chain CD3 binding moiety comprises SEQ ID NO: 23; and/or
the VH in the single-chain CD20 binding moiety comprises SEQ ID NO: 24, and the VL in the single-chain CD20 binding moiety comprises SEQ ID NO: 25.

### Claim 3 (depends on 1)

The bispecific antibody of claim 1, wherein the first and/or second peptide linker comprises SEQ ID NO: 13.

### Claim 4 (depends on 1)

The bispecific antibody of claim 1, further comprising a CH1 domain and a CK domain, wherein the CH1 domain and the CK domain forms a heterodimer.

### Claim 5 (depends on 4)

The bispecific antibody of claim 4, wherein the VH in the single-chain CD3 binding moiety is operably linked to the CH1 domain via a third peptide linker, and wherein the VH in the single-chain CD20 binding moiety is operably linked to the CK domain via a fourth peptide linker.

### Claim 6 (depends on 5)

The bispecific antibody of claim 5, wherein the third and/or fourth peptide linker comprises SEQ ID NO: 14.

### Claim 7 (depends on 6)

The bispecific antibody of claim 6, comprising a first polypeptide sequence comprising SEQ ID NO: 15, and a second polypeptide comprising SEQ ID NO: 16.

### Claim 8 (depends on 4)

The bispecific antibody of claim 4, wherein the VL in the single-chain CD3 binding moiety is operably linked to the CH1 domain via a third peptide linker, and wherein the VL in the single-chain CD20 binding moiety is operably linked to the CK domain via a fourth peptide linker.

### Claim 9 (depends on 8)

The bispecific antibody of claim 8, wherein the third and/or fourth peptide linker comprises SEQ ID NO: 14.

### Claim 10 (depends on 9)

The bispecific antibody of claim 9, comprising a first polypeptide sequence comprising SEQ ID NO: 17, and a second polypeptide comprising SEQ ID NO: 18.

### Claim 11 (depends on 1)

The bispecific antibody of claim 1, further comprising an Fc region comprising a first and second CH2 domain and a first and second CH3 domain.

### Claim 12 (depends on 11)

The bispecific antibody of claim 11, wherein the VL in the single-chain CD3 binding moiety is operably linked to the first CH2 domain via a third peptide linker, and wherein the VL in the single-chain CD20 binding moiety is operably linked to the second CH2 domain via a fourth peptide linker.

### Claim 13 (depends on 12)

The bispecific antibody of claim 12, wherein the third and/or fourth peptide linker comprises SEQ ID NO: 19.

### Claim 14 (depends on 11)

The bispecific antibody of claim 11, wherein the first and second CH2 domain comprises a L234A and/or L235A mutation.

### Claim 15 (depends on 14)

The bispecific antibody of claim 14, comprising a first polypeptide sequence comprising SEQ ID NO: 20, and a second polypeptide comprising SEQ ID NO: 21.

### Claim 16 (depends on 1)

An isolated polynucleotide encoding the single-chain CD3 binding moiety and/or the single-chain CD20 binding moiety of the bispecific antibody of claim 1.

### Claim 17 (depends on 1)

A vector comprising one or more polynucleotides encoding the bispecific antibody of claim 1.

### Claim 18 (depends on 1)

A composition comprising the bispecific antibody of claim 1.

### Claim 19 (depends on 1)

A pharmaceutical composition comprising the bispecific antibody of claim 1 and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 1)

A host cell capable of expressing the bispecific antibody of claim 1.

### Claim 21 (depends on 20)

A method of producing a bispecific antibody, comprising culturing the host cell of claim 20 and recovering the bispecific antibody from the host cell.

### Claim 22 (depends on 1)

A method of treating a subject suffering from a B cell-related cancer, comprising administrating to the subject a therapeutically effective amount of the bispecific antibody of claim 1.

### Claim 23 (depends on 22)

The method of claim 22, wherein the B cell-related cancer is selected from Hodgkin's lymphoma, non-Hodgkin's lymphoma, precursor B cell lymphoblastic leukemia/lymphoma, mature B cell neoplasms, B cell chronic lymphocytic leukemia, small lymphocytic lymphoma, B cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, mantle cell lymphoma, follicular lymphoma, cutaneous follicle center lymphoma, marginal zone B cell lymphoma, hairy cell leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, plasmacytoma, plasma cell myeloma, post-transplant lymphoproliferative disorder, Waldenstrom's macroglobulinemia, and anaplastic large-cell lymphoma.

### Claim 24 (depends on 22)

The method of claim 22, wherein the subject has developed resistance to anti-CD20 therapy.

### Claim 25 (depends on 22)

The method of claim 22, wherein the subject has developed resistance to rituximab therapy.

### Claim 26 (depends on 22)

The method of claim 22, wherein the treatment results in significant or complete cancer remission.
